To appraise the clinical and cost effectiveness of:Nivolumab in combination with rucaparib, docetaxel or enzalutamide within its marketing authorisation for prostate cancer
Status In progress
Decision Selected
Process STA 2018
ID number 1619


Key events during the development of the guidance:

Date Update
12 February 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619] The company have advised that they will not be pursuing a Marketing Authorisation Application for nivolumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred, NICE will continue to monitor the situation and update interested parties if the situation changes.
09 May 2019 In progress. Referred 29 April 2019

For further information on our processes and methods, please see our CHTE processes and methods manual